Summary of primary bone marrow transplantation experiments
Construct . | Donor background . | No. . | Median survival, days . | GFP, % at 3 weeks* . | WBC count, × 103/μL . | Spleen weight, mg . | Phenotype . |
|---|---|---|---|---|---|---|---|
| Myc | B6 129 Ink−/− | 10 | 28 ± 1.1 | 79.5 ± 2.7 | 65.5 ± 20.7 | 214 ± 50 | AML + ALL |
| Myc | B6 129 Ink+/+ | 10 | 61 ± 3.7 | 56.2 ± 3.9 | 6.0 ± 1.4 | 380 ± 40 | AML |
| GFP | B6 129 Ink−/− | 10 | >200 | 40.5 ± 2.8 | 2.9 ± 0.4 | NA | NA |
| GFP | B6 129 Ink+/+ | 6 | >200 | 78.2 ± 5.4 | 6.2 ± 0.6 | NA | NA |
| Myc + Bcl2 | BALB/c | 33 | 16 ± 0.7 | NA† | 113.7 ± 18.8 | 355 ± 15 | AML + ALL |
| Myc | BALB/c | 35 | 47 ± 2.9 | 86.9 ± 0.6 | 12.3 ± 1.5 | 386 ± 30 | AML |
| Bcl-2 | BALB/c | 10 | >200 | 76.3 ± 3.2 | 9.9 ± 0.7 | NA | NA |
Construct . | Donor background . | No. . | Median survival, days . | GFP, % at 3 weeks* . | WBC count, × 103/μL . | Spleen weight, mg . | Phenotype . |
|---|---|---|---|---|---|---|---|
| Myc | B6 129 Ink−/− | 10 | 28 ± 1.1 | 79.5 ± 2.7 | 65.5 ± 20.7 | 214 ± 50 | AML + ALL |
| Myc | B6 129 Ink+/+ | 10 | 61 ± 3.7 | 56.2 ± 3.9 | 6.0 ± 1.4 | 380 ± 40 | AML |
| GFP | B6 129 Ink−/− | 10 | >200 | 40.5 ± 2.8 | 2.9 ± 0.4 | NA | NA |
| GFP | B6 129 Ink+/+ | 6 | >200 | 78.2 ± 5.4 | 6.2 ± 0.6 | NA | NA |
| Myc + Bcl2 | BALB/c | 33 | 16 ± 0.7 | NA† | 113.7 ± 18.8 | 355 ± 15 | AML + ALL |
| Myc | BALB/c | 35 | 47 ± 2.9 | 86.9 ± 0.6 | 12.3 ± 1.5 | 386 ± 30 | AML |
| Bcl-2 | BALB/c | 10 | >200 | 76.3 ± 3.2 | 9.9 ± 0.7 | NA | NA |
Numbers are shown as ± standard deviation.
NA indicates not applicable; WBC, white blood cell; AML, acute myeloid leukemia; ALL, acute lymphoid leukemia.
The percentage of GFP-positive peripheral-blood leukocytes measured by flow cytometry 3 weeks after marrow transplantation.
The MSCV-Myc + Bcl2 construct does not contain GFP.